NCT01960699

Brief Summary

Background: Cardiac arrest is a life-threatening event. Intensivists are challenged with an increasing number of patients with uncertain neurological outcome following cardiopulmonary resuscitation (CPR). The prognostic value of current biomarkers for neurophysiologic long-term outcome is limited. Hypothesis: We hypothesize that specific brain-derived tissue leakage proteins can be identified to reveal novel, more reliable prognostic biomarkers for good neurological outcome. Methods: This translational study (n=100) is a combination of a prospective basic science study intended to reduce the number of potential plasma biomarker candidates by proteomic shotgun analyses in brain tissue autopsy samples and plasma samples from resuscitated patients (n=10) and a prospective clinical validation study in a large study population (n=90) by high-throughput analyses. Selection of proteomic markers and signature estimation will be performed to discriminate patients with good and poor outcome. Clinical perspective: A structured proteomic analysis approach might identify the best marker out of all proteins liberated during cellular damage.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
96

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2013

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2013

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

October 8, 2013

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 11, 2013

Completed
6.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

February 24, 2020

Status Verified

February 1, 2020

Enrollment Period

6.3 years

First QC Date

October 8, 2013

Last Update Submit

February 20, 2020

Conditions

Keywords

PrognosisNeurological outcomeResuscitationBiomarker

Outcome Measures

Primary Outcomes (1)

  • Cerebral performance categories (CPC)of <3

    participants will be followed for the duration of intensive-care unit stay, an expected average of 2 weeks.

Secondary Outcomes (1)

  • Cerebral performance categories (CPC)of <3

    6 Months

Other Outcomes (2)

  • Brain glucose metabolism

    Day 1 after end of cooling period

  • Clinical outcome (rehospitalization and death)

    3 years

Study Arms (2)

CPC < 3

Good neurological outcome

CPC >/= 3

Unvavourable neurologic outcome

Eligibility Criteria

Age18 Years - 99 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Resuscitated patients

You may qualify if:

  • Nontraumatic, normothermic cardiac arrest due to cardiac disorders, respiratory failures, or hemodynamic or metabolic factors.
  • A Glasgow Coma Scale of 3, none of the patients will be conscious at the time of hospital admission.
  • No previous cardiac arrest, as well as known or coexisting neurological disorders or neoplasms of the central nervous system.
  • No history of psychiatric illness, no alcohol or drug dependency, and no psychotropic medication.
  • Initiation of mild therapeutic hypothermia

You may not qualify if:

  • hydrocephalus and shunt artifact
  • severe movement artifacts
  • intracerebral hemorrhage
  • old large ischemic lesion

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Medical University of Vienna

Vienna, 1090, Austria

Location

Related Publications (1)

  • Distelmaier K, Muqaku B, Wurm R, Arfsten H, Seidel S, Kovacs GG, Mayer RL, Szekeres T, Wallisch C, Hubner P, Goliasch G, Heinze G, Heinz G, Sterz F, Gerner C, Adlbrecht C. Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors. Crit Care Med. 2020 Feb;48(2):167-175. doi: 10.1097/CCM.0000000000004105.

Biospecimen

Retention: SAMPLES WITHOUT DNA

Plasma samples stored at -80°C

Study Officials

  • Christopher Adlbrecht, MD

    Medical University of Vienna

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
3 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PI

Study Record Dates

First Submitted

October 8, 2013

First Posted

October 11, 2013

Study Start

October 1, 2013

Primary Completion

January 1, 2020

Study Completion

January 1, 2020

Last Updated

February 24, 2020

Record last verified: 2020-02

Locations